Related references
Note: Only part of the references are listed.KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
A. I. Phipps et al.
BRITISH JOURNAL OF CANCER (2013)
Clinical Utility of KRAS and BRAF Mutations in a Cohort of Patients With Colorectal Neoplasms Submitted for Microsatellite Instability Testing
Allison M. Cushman-Vokoun et al.
CLINICAL COLORECTAL CANCER (2013)
Predictive and Prognostic Roles of BRAF Mutation in Stage III Colon Cancer: Results from Intergroup Trial CALGB 89803
Shuji Ogino et al.
CLINICAL CANCER RESEARCH (2012)
Specific Mutations in KRAS Codons 12 and 13, and Patient Prognosis in 1075 BRAF Wild-Type Colorectal Cancers
Yu Imamura et al.
CLINICAL CANCER RESEARCH (2012)
Is K-ras Gene Mutation a Prognostic Factor for Colorectal Cancer: A Systematic Review and Meta-analysis
JiaoJiao Ren et al.
DISEASES OF THE COLON & RECTUM (2012)
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
Carsten Bokemeyer et al.
EUROPEAN JOURNAL OF CANCER (2012)
Clinicopathologic features and prognostic analysis of MSI-high colon cancer
Chun-Chi Lin et al.
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE (2012)
BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy
Hao-Wei Teng et al.
JOURNAL OF SURGICAL ONCOLOGY (2012)
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
T. Yokota et al.
BRITISH JOURNAL OF CANCER (2011)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Effect of KRAS Mutational Status in Advanced Colorectal Cancer on the Outcomes of Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: A Systematic Review and Meta-analysis
Albert Y. Lin et al.
CLINICAL COLORECTAL CANCER (2011)
Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer
Timothy J. Price et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Epigenetics and colorectal cancer
Victoria Valinluck Lao et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer
Simon A. Forbes et al.
NUCLEIC ACIDS RESEARCH (2011)
Biomarker-Based Prediction of Response to Therapy for Colorectal Cancer Current Perspective
Jeffrey S. Ross et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2010)
The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients
A. Farina-Sarasqueta et al.
ANNALS OF ONCOLOGY (2010)
KRAS Mutation and Microsatellite Instability: Two Genetic Markers of Early Tumor Development That Influence the Prognosis of Colorectal Cancer
Garrett M. Nash et al.
ANNALS OF SURGICAL ONCOLOGY (2010)
Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy
Seung Tae Kim et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Combined analysis of specific KRAS mutation, BRAF and microsatellite instability identifies prognostic subgroups of sporadic and hereditary colorectal cancer
Inti Zlobec et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Prognostic Role of KRAS and BRAF in Stage II and III Resected Colon Cancer: Results of the Translational Study on the PETACC-3, EORTC 40993, SAKK 60-00 Trial
Arnaud D. Roth et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Revised TN Categorization for Colon Cancer Based on National Survival Outcomes Data
Leonard L. Gunderson et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Microsatellite instability in colorectal cancer-the stable evidence
Eduardo Vilar et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2010)
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
F. Loupakis et al.
BRITISH JOURNAL OF CANCER (2009)
CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer
Shuji Ogino et al.
GUT (2009)
KRAS and BRAF Mutations in Advanced Colorectal Cancer Are Associated With Poor Prognosis but Do Not Preclude Benefit From Oxaliplatin or Irinotecan: Results From the MRC FOCUS Trial
Susan D. Richman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Implications for KRAS status and EGFR-targeted therapies in metastatic CRC
Nicola Normanno et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
BRAF Mutation in Metastatic Colorectal Cancer.
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Jolien Tol et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Different types of K-Ras mutations are conversely associated with overall survival in patients with colorectal cancer
Thomas Winder et al.
ONCOLOGY REPORTS (2009)
Prognostic significance of defective mismatch repair and BRAF V600E in patients with colon cancer
Amy J. French et al.
CLINICAL CANCER RESEARCH (2008)
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Federica Di Nicolantonio et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation
Sun Lee et al.
PATHOLOGY INTERNATIONAL (2008)
Transformation efficiency of RasQ61 mutants linked to structural features of the switch regions in the presence of Raf
Greg Buhrman et al.
STRUCTURE (2007)
Hyperactive Ras in developmental disorders and cancer
Suzanne Schubbert et al.
NATURE REVIEWS CANCER (2007)
Distinctive clinicopathological features of Ki-ras mutated colorectal cancers
Jen-Kou Lin et al.
JOURNAL OF SURGICAL ONCOLOGY (2006)
Recurrent KRAS Codon 146 mutations in human colorectal cancer
Sarah Edkins et al.
CANCER BIOLOGY & THERAPY (2006)
CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer
Daniel J. Weisenberger et al.
NATURE GENETICS (2006)
Relationship between genetic alterations and prognosis in sporadic colorectal cancer
SC Chang et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
The prognostic significance of K-ras, p53, and APC mutations in colorectal carcinoma
A Conlin et al.
GUT (2005)
Determination of TP53 mutation is more relevant than microsatellite instability status for the prediction of disease-free survival in adjuvant-treated stage III colon cancer patients
JL Westra et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
WS Samowitz et al.
CANCER RESEARCH (2005)
Systematic review of microsatellite instability and colorectal cancer prognosis
S Popat et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Activated BRAF targets proximal colon tumors with mismatch repair deficiency and MLH1 inactivation
E Domingo et al.
GENES CHROMOSOMES & CANCER (2004)
Distinct patterns of KRAS mutations in colorectal carcinomas according to germline mismatch repair defects and hMLH1 methylation status
C Oliveira et al.
HUMAN MOLECULAR GENETICS (2004)
Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer
CM Ribic et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype
V Bazan et al.
ANNALS OF ONCOLOGY (2002)
The Raf/MEK/ERK pathway:: new concepts of activation
C Peyssonnaux et al.
BIOLOGY OF THE CELL (2001)
Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study
HJN Andreyev et al.
BRITISH JOURNAL OF CANCER (2001)
Histopathological identification of colon cancer with microsatellite instability
J Alexander et al.
AMERICAN JOURNAL OF PATHOLOGY (2001)
Share Paper
